All News

Student pharmacists should use practical tips to responsibly use artificial intelligence tools for studying, clinical simulations, exam preparation, and time management while ensuring ethical and effective usage.

Explore the evolving role of pharmacists in navigating FDA regulations and the impact of drug ads on patient care.

New results from the phase 3 HYPERION trial demonstrate reduced risks as early as the year following diagnosis of pulmonary arterial hypertension.

The approval is supported by findings from the INTEGUMENT-PED trial and the INTEGUMENT-OLE long-term extension study.

Martha Thorne discusses the operational, financial, and patient care challenges pharmacies face under the 340B rebate pilot and the need for advocacy, automation, and transparency to sustain access.

The angiopoietin-like-3-targeting treatment received an expanded indication for individuals aged 1 through 5 years, building on earlier approvals in older populations.

Derek Webb, PharmD, discusses RSV in older adults, highlighting symptoms, risk factors, and barriers to vaccination.

Recent research reveals that continuous glucose monitors (CGMs) may inaccurately overestimate blood sugar levels, potentially leading to unnecessary dietary changes for healthy individuals.

Pulmonary fibrosis was observed in many patients with severe COVID-19 in a retrospective cohort study, indicating the need for more effective care and prevention.

A phase 3 study shows SYSA1902, a biosimilar to Stelara, is clinically equivalent for treating moderate to severe plaque psoriasis.

This is the second generic version of mifepristone to be approved by the FDA.

Investigators found inconsistencies across subgroups, but the overall efficacy and safety of pneumococcal vaccination was affirmed.

Matthew D. Clark, PharmD, highlights a pharmacist-led program that improved opioid safety in cancer care despite regulatory exemptions.

Discover how pharmacists play a crucial role in the OUD treatment process with buprenorphine, enhancing patient care and recovery outcomes.

MD Anderson's opioid stewardship program enhances patient safety and care by monitoring opioid use, addressing discrepancies, and fostering multidisciplinary collaboration in cancer treatment.

The approval was based on positive efficacy and safety indications from the IMforte clinical trial of patients with extensive-stage small cell lung cancer (SCLC).

FDA enhances oversight of drug ads using AI to ensure compliance, addressing risks and benefits in direct-to-consumer advertising.

Metabolic bariatric surgery offers greater weight loss and lower costs than GLP-1 treatments for obesity, prompting a reevaluation of treatment strategies.

Recent findings reveal that stereotactic radiation therapy (SABR) offers long-term survival outcomes comparable to surgery in patients with early non–small cell lung cancer (NSCLC).

Researchers uncover how apolipoprotein D (ApoD) increases influenza severity in older adults, highlighting the need for enhanced vaccines and new therapeutic strategies.

In chronic kidney disease (CKD), SDMA showed a stronger connection to vascular health compared with ADMA.

The RNA interference therapy indicated that, along with its therapeutic benefits in cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM), there was a reduced risk of GI events.

Gene therapy offers transformative potential in treating diseases like sickle cell and leukemia, highlighting pharmacists' crucial roles.

New research links oral bacteria and fungi to pancreatic cancer risk, suggesting oral microbiota as potential noninvasive biomarkers for early detection.

Gene therapy revolutionizes treatment in oncology, highlighting pharmacists' vital roles in patient care and long-term monitoring.

In an announcement at the White House, Pfizer said it will reduce drug prices in the United States to match those of other countries.

In this video, experts who attended the 2025 International Myeloma Society (IMS) Annual Meeting highlighted topics of interest as well as pivotal data.

A real-world study at MSK reveals promising efficacy and safety of second-generation BTK inhibitors in mantle cell lymphoma treatment, influencing future guidelines.